Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Leukemia

  Free Subscription


Articles published in Exp Hematol

Retrieve available abstracts of 76 articles:
HTML format
Text format



Single Articles


    July 2019
  1. HONG CS, Danet-Desnoyers G, Shan X, Sharma P, et al
    Human acute myeloid leukemia blast-derived exosomes in patient derived xenograft mice mediate immune suppression.
    Exp Hematol. 2019 Jul 29. pii: S0301-472X(19)30918.
    PubMed     Text format     Abstract available


  2. JAFEK JL, Shakya A, Tai PY, Ibarra A, et al
    Transcription factor Oct1 protects against hematopoietic stress and promotes acute myeloid leukemia.
    Exp Hematol. 2019 Jul 8. pii: S0301-472X(19)30855.
    PubMed     Text format    


    June 2019
  3. VAIKARI VP, Yang J, Wu S, Alachkar H, et al
    CD97 is associated with poor overall survival in Acute Myeloid Leukemia.
    Exp Hematol. 2019 Jun 28. pii: S0301-472X(19)30802.
    PubMed     Text format     Abstract available


  4. AHN JS, Kim T, Kim YK, Cho YC, et al
    Remission clone in acute myeloid leukemia shows growth advantage after chemotherapy but is distinct from leukemic clone.
    Exp Hematol. 2019 Jun 11. pii: S0301-472X(19)30329.
    PubMed     Text format     Abstract available


    May 2019
  5. MILAN T, Canaj HV, Villeneuve C, Ghosh A, et al
    Pediatric Leukemia: moving towards more accurate models.
    Exp Hematol. 2019 May 30. pii: S0301-472X(19)30320.
    PubMed     Text format     Abstract available


  6. ANDERSON E, Rees B, Hull J, Heywood J, et al
    Intracellular cytarabine triphosphate in circulating blasts post-treatment predicts remission status in patients with acute myeloid leukemia.
    Exp Hematol. 2019 May 2. pii: S0301-472X(19)30191.
    PubMed     Text format     Abstract available


    April 2019
  7. BARBOSA K, Deshpande A, Chen BR, Ghosh A, et al
    Acute Myeloid Leukemia Driven by the CALM-AF10 Fusion Gene is Dependent on BMI1.
    Exp Hematol. 2019 Apr 22. pii: S0301-472X(19)30187.
    PubMed     Text format     Abstract available


  8. XU LS, Francis A, Turkistany S, Shukla D, et al
    ETV6-RUNX1 interacts with a region in SPIB intron 1 to regulate gene expression in pre-B cell acute lymphoblastic leukemia.
    Exp Hematol. 2019 Apr 12. pii: S0301-472X(19)30134.
    PubMed     Text format     Abstract available


    February 2019
  9. HERNANDEZ-SANCHEZ M, Rodriguez-Vicente AE, Gonzalez-Gascon Y Marin I, Quijada-Alamo M, et al
    DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia patients and chromosomal gains.
    Exp Hematol. 2019 Feb 23. pii: S0301-472X(19)30073.
    PubMed     Text format     Abstract available


  10. SHAPIRA S, Raanani P, Samara A, Nagler A, et al
    Deferasirox selectively induces cell death in the clinically relevant population of leukemic CD34(+)CD38(-) cells through iron chelation, induction of ROS, and inhibition of HIF1alpha expression.
    Exp Hematol. 2019;70:55-69.
    PubMed     Text format     Abstract available


    January 2019
  11. TURHAN AG, Foudi A, Hwang JW, Desterke C, et al
    MODELING MALIGNANCIES USING INDUCED PLURIPOTENT STEM CELLS: FROM CHRONIC MYELOID LEUKEMIA (CML) TO HEREDITARY CANCERS.
    Exp Hematol. 2019 Jan 16. pii: S0301-472X(19)30008.
    PubMed     Text format     Abstract available


  12. DANNENMANN B, Zahabi A, Mir P, Oswald B, et al
    Human iPSC-based model of severe congenital neutropenia reveals elevated UPR and DNA damage in CD34(+) cells preceding leukemic transformation.
    Exp Hematol. 2019 Jan 4. pii: S0301-472X(19)30004.
    PubMed     Text format     Abstract available


  13. LUCIANI GM, Xie L, Dilworth D, Tierens A, et al
    Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression.
    Exp Hematol. 2019;69:27-36.
    PubMed     Text format     Abstract available


    December 2018
  14. GUILLAUME T, Dehame V, Chevallier P, Peterlin P, et al
    Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies.
    Exp Hematol. 2018 Dec 26. pii: S0301-472X(18)30987.
    PubMed     Text format     Abstract available


    November 2018
  15. SHANG J, Chen WM, Wang ZH, Wei TN, et al
    CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p/miR-183-5p-XIAP axis.
    Exp Hematol. 2018 Nov 2. pii: S0301-472X(18)30873.
    PubMed     Text format     Abstract available


  16. BARVE A, Casson L, Krem M, Wunderlich M, et al
    Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response.
    Exp Hematol. 2018;67:18-31.
    PubMed     Text format     Abstract available


  17. VALDEZ BC, Tang X, Li Y, Murray D, et al
    Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.
    Exp Hematol. 2018;67:49-59.
    PubMed     Text format     Abstract available


    October 2018
  18. CHEN Y, Jones KL, Anastassiadis K, Kranz A, et al
    Distinct Pathways Affected by Menin versus MLL1/MLL2 in MLL-rearranged Acute Myeloid Leukemia.
    Exp Hematol. 2018 Oct 10. pii: S0301-472X(18)30851.
    PubMed     Text format     Abstract available


  19. GHORASHIAN S, Amrolia P, Veys P
    Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL.
    Exp Hematol. 2018;66:5-16.
    PubMed     Text format     Abstract available


  20. SALOME M, Hopcroft L, Keeshan K
    Inverse and correlative relationships between TRIBBLES genes indicate non-redundant functions during normal and malignant hemopoiesis.
    Exp Hematol. 2018;66:63-78.
    PubMed     Text format     Abstract available


    September 2018
  21. SENFT D, Jeremias I
    A rare subgroup of leukemia stem cells harbours relapse-inducing potential in acute lymphoblastic leukemia.
    Exp Hematol. 2018 Sep 24. pii: S0301-472X(18)30807.
    PubMed     Text format     Abstract available


  22. LI X, Xu L, Shen X, Cai J, et al
    Up-regulated miR-146a expression induced by G-CSF enhanced low dosage chemotherapy response in aged acute myeloid leukemia patients.
    Exp Hematol. 2018 Sep 9. pii: S0301-472X(18)30799.
    PubMed     Text format     Abstract available


  23. PAN B, Yang J, Wang X, Xu K, et al
    miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2.
    Exp Hematol. 2018 Sep 5. pii: S0301-472X(18)30798.
    PubMed     Text format     Abstract available


  24. HEIBLIG M, Rea D, Chretien ML, Charbonnier A, et al
    Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: The PEARL observational study.
    Exp Hematol. 2018 Sep 5. pii: S0301-472X(18)30795.
    PubMed     Text format     Abstract available


    August 2018
  25. GAO S, Zhou B, Li H, Huang X, et al
    Long non-coding RNA HOTAIR promotes the self-renewal of leukemia stem cell through epigenetic silencing of p15.
    Exp Hematol. 2018 Aug 30. pii: S0301-472X(18)30752.
    PubMed     Text format     Abstract available


  26. BORGES CS, Ferreira AF, Almeida VH, Gomes FG, et al
    CROSSTALK BETWEEN BCR-ABL AND PROTEASE-ACTIVATED RECEPTOR 1 (PAR1) SUGGESTS A NOVEL TARGET IN CHRONIC MYELOID LEUKEMIA.
    Exp Hematol. 2018 Aug 1. pii: S0301-472X(18)30746.
    PubMed     Text format     Abstract available


    July 2018
  27. KOTB A, Fakih RE, Hanbali A, Hawsawi Y, et al
    Philadelphia-Like Acute Lymphoblastic Leukemia: Diagnostic dilemma and management perspectives.
    Exp Hematol. 2018 Jul 31. pii: S0301-472X(18)30743.
    PubMed     Text format     Abstract available


  28. AZOULAY D, Herishanu Y, Shapiro M, Brandshaft Y, et al
    Elevated serum BDNF levels are associated with favorable outcome in CLL patients: Possible link to CXCR4 downregulation.
    Exp Hematol. 2018;63:17-21.
    PubMed     Text format     Abstract available


  29. WESTON VJ, Wei W, Stankovic T, Kearns P, et al
    Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1.
    Exp Hematol. 2018;63:52-63.
    PubMed     Text format     Abstract available


    June 2018
  30. NARAYAN N, Bracken CP, Ekert PG
    MicroRNA-155 expression and function in AML: An evolving paradigm.
    Exp Hematol. 2018;62:1-6.
    PubMed     Text format     Abstract available


    May 2018
  31. NICOLINI FE, Alcazer V, Cony-Makhoul P, Heiblig M, et al
    Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on imatinib first-line.
    Exp Hematol. 2018 May 22. pii: S0301-472X(18)30259.
    PubMed     Text format     Abstract available


  32. SHI X, Kitano A, Jiang Y, Luu V, et al
    Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells.
    Exp Hematol. 2018 May 8. pii: S0301-472X(18)30256.
    PubMed     Text format     Abstract available


  33. JENKINS CE, Gusscott S, Wong RJ, Shevchuk OO, et al
    RUNX1 promotes cell growth in human T-cell acute lymphoblastic leukemia by transcriptional regulation of key target genes.
    Exp Hematol. 2018 May 4. pii: S0301-472X(18)30217.
    PubMed     Text format     Abstract available


  34. DESTERKE C, Voldoire M, Bonnet ML, Sorel N, et al
    Experimental and integrative analyses identify an ETS1 network downstream BCR-ABL in chronic myeloid leukemia (CML).
    Exp Hematol. 2018 May 4. pii: S0301-472X(18)30216.
    PubMed     Text format     Abstract available


  35. MIHALYOVA J, Jelinek T, Growkova K, Hrdinka M, et al
    Venetoclax: A new wave in hematooncology.
    Exp Hematol. 2018;61:10-25.
    PubMed     Text format     Abstract available


    April 2018
  36. THURGOOD LA, Lower KM, Macardle C, Kuss BJ, et al
    Aberrant detection of phenotypic markers in chronic lymphocytic leukemia (CLL) lymphocytes following cryopreservation.
    Exp Hematol. 2018 Apr 26. pii: S0301-472X(18)30172.
    PubMed     Text format     Abstract available


  37. TIJCHON E, van Emst L, Yuniati L, van Ingen Schenau D, et al
    Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.
    Exp Hematol. 2018;60:57-62.
    PubMed     Text format     Abstract available


    March 2018
  38. NEWCOMBE AA, Gibson BES, Keeshan K
    Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia.
    Exp Hematol. 2018 Mar 30. pii: S0301-472X(18)30166.
    PubMed     Text format     Abstract available


  39. ORTI G, Sanz J, Garcia-Cadenas I, Sanchez-Ortega I, et al
    Analysis of relapse post transplant in acute leukemia, a comparative on second allogeneic hematopoietic cell transplant and donor lymphocyte infusions.
    Exp Hematol. 2018 Mar 8. pii: S0301-472X(18)30120.
    PubMed     Text format     Abstract available


    February 2018
  40. ZYLBERSZTEJN F, Flores-Violante M, Voeltzel T, Nicolini FE, et al
    The BMP pathway: a unique tool to decode origin and progression of leukemia.
    Exp Hematol. 2018 Feb 22. pii: S0301-472X(18)30077.
    PubMed     Text format     Abstract available


  41. LI H, Xing C, Zhou B, Ye H, et al
    A regulatory circuitry between miR-193a/miR-600 and WT1 enhances leukemogenesis in acute myeloid leukemia.
    Exp Hematol. 2018 Feb 13. pii: S0301-472X(18)30041.
    PubMed     Text format     Abstract available


  42. DUSSIAU C, Fontenay M
    Mechanisms underlying the heterogeneity of myelodysplastic syndromes.
    Exp Hematol. 2018;58:17-26.
    PubMed     Text format     Abstract available


    January 2018
  43. GONG Y, Zhao M, Yang W, Gao A, et al
    Megakaryocyte-derived excessive TGFbeta1 inhibits proliferation of normal hematopoietic stem cells in acute myeloid leukemia.
    Exp Hematol. 2018 Jan 4. pii: S0301-472X(17)30909.
    PubMed     Text format     Abstract available


    December 2017
  44. GRIESSINGER E, Vargaftig J, Horswell S, Taussig DC, et al
    Acute myeloid leukemia xenograft success prediction: saving time.
    Exp Hematol. 2017 Dec 15. pii: S0301-472X(17)30900.
    PubMed     Text format     Abstract available


    November 2017
  45. CASTAGNA L, Devillier R, Vey N, Blaise D, et al
    T cell replete-haploidentical transplantation in acute myeloid leukemia.
    Exp Hematol. 2017 Nov 16. pii: S0301-472X(17)30861.
    PubMed     Text format     Abstract available


  46. CULL AH, Snetsinger B, Buckstein R, Wells RA, et al
    Tet2 restrains inflammatory gene expression in macrophages.
    Exp Hematol. 2017;55:56-70.
    PubMed     Text format     Abstract available


    October 2017
  47. BOILA LD, Chatterjee SS, Banerjee D, Sengupta A, et al
    KDM6 and KDM4 histone lysine demethylases emerge as molecular therapeutic targets in human acute myeloid leukemia.
    Exp Hematol. 2017 Oct 27. pii: S0301-472X(17)30824.
    PubMed     Text format     Abstract available


  48. WILLMANN M, Sadovnik I, Eisenwort G, Entner M, et al
    Evaluation of cooperative anti-leukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia.
    Exp Hematol. 2017 Oct 12. pii: S0301-472X(17)30816.
    PubMed     Text format     Abstract available


  49. HASSAN C, Afshinnekoo E, Li S, Wu S, et al
    Genetic and epigenetic heterogeneity and the impact on cancer relapse.
    Exp Hematol. 2017;54:26-30.
    PubMed     Text format     Abstract available


    September 2017
  50. GREGORY MA, Nemkov T, Reisz JA, Zaberezhnyy V, et al
    Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
    Exp Hematol. 2017 Sep 22. pii: S0301-472X(17)30776.
    PubMed     Text format     Abstract available


  51. LAGACE K, Barabe F, Hebert J, Cellot S, et al
    Identification of novel biomarkers for MLL translocated acute myeloid leukemia.
    Exp Hematol. 2017 Sep 11. pii: S0301-472X(17)30758.
    PubMed     Text format     Abstract available


  52. CHAN LN, Muschen M
    B-cell identity as a metabolic barrier against malignant transformation.
    Exp Hematol. 2017;53:1-6.
    PubMed     Text format     Abstract available


    August 2017
  53. HEROLD N, Rudd SG, Sanjiv K, Kutzner J, et al
    With me or against me: Tumor suppressor and drug resistance activities of SAMHD1.
    Exp Hematol. 2017;52:32-39.
    PubMed     Text format     Abstract available


  54. KIM YM, Gang EJ, Kahn M
    CBP/Catenin antagonists: Targeting LSCs' Achilles heel.
    Exp Hematol. 2017;52:1-11.
    PubMed     Text format     Abstract available


    July 2017
  55. ZHANG J, Griffith M, Miller CA, Griffith OL, et al
    Comprehensive discovery of non-coding RNAs in acute myeloid leukemia cell transcriptomes.
    Exp Hematol. 2017 Jul 28. pii: S0301-472X(17)30701.
    PubMed     Text format     Abstract available


  56. YALCIN A, Kovarbasic M, Wehrle J, Claus R, et al
    The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.
    Exp Hematol. 2017 Jul 28. pii: S0301-472X(17)30702.
    PubMed     Text format     Abstract available


  57. MARTINO B, Mammi C, Labate C, Rodi S, et al
    Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib.
    Exp Hematol. 2017 Jul 28. pii: S0301-472X(17)30663.
    PubMed     Text format     Abstract available


  58. CARRETTA M, de Boer B, Jaques J, Antonelli A, et al
    Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models.
    Exp Hematol. 2017;51:36-46.
    PubMed     Text format     Abstract available


  59. LEPRETRE S, Graux C, Touzart A, Macintyre E, et al
    Adult T-type lymphoblastic lymphoma: Treatment advances and prognostic indicators.
    Exp Hematol. 2017;51:7-16.
    PubMed     Text format     Abstract available


    June 2017
  60. LAING AA, Harrison CJ, Gibson BES, Keeshan K, et al
    Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia.
    Exp Hematol. 2017 Jun 28. pii: S0301-472X(17)30237.
    PubMed     Text format     Abstract available


  61. SANDA T, Leong WZ
    TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia.
    Exp Hematol. 2017 Jun 23. pii: S0301-472X(17)30231.
    PubMed     Text format     Abstract available


  62. SLOMA I, Mitjavila-Garcia M, Feraud O, Griscelli F, et al
    Whole genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia.
    Exp Hematol. 2017 Jun 7. pii: S0301-472X(17)30192.
    PubMed     Text format     Abstract available


  63. PORTER SN, Magee JA
    PRKCH regulates hematopoietic stem cell function and predicts poor prognosis in acute myeloid leukemia.
    Exp Hematol. 2017 Jun 5. pii: S0301-472X(17)30190.
    PubMed     Text format     Abstract available


    May 2017
  64. OMORI I, Yamaguchi H, Miyake K, Miyake N, et al
    D816V mutation in the KIT gene activation loop has a greater cell proliferative and anti-apoptotic ability than N822K mutation in core binding factor-acute myeloid leukemia.
    Exp Hematol. 2017 May 12. pii: S0301-472X(17)30146.
    PubMed     Text format     Abstract available


  65. SHEN Y, Chen TJ, Lacorazza HD
    Novel tumor suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia.
    Exp Hematol. 2017 May 4. pii: S0301-472X(17)30141.
    PubMed     Text format     Abstract available


    April 2017
  66. SADOVNIK I, Herrmann H, Eisenwort G, Blatt K, et al
    Expression of CD25 on Leukemic Stem Cells in BCR-ABL1+ CML: Potential Diagnostic Value and Functional Implications.
    Exp Hematol. 2017 Apr 27. pii: S0301-472X(17)30135.
    PubMed     Text format     Abstract available


  67. VAN GILS N, Verhagen HJMP, Smit L
    Reprogramming acute myeloid leukemia into sensitivity for retinoic acid-driven differentiation.
    Exp Hematol. 2017 Apr 26. pii: S0301-472X(17)30139.
    PubMed     Text format     Abstract available


  68. SASAKI T, Rivera-Mulia JC, Vera D, Zimmerman J, et al
    Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia.
    Exp Hematol. 2017 Apr 19. pii: S0301-472X(17)30136.
    PubMed     Text format     Abstract available


  69. CHOI EJ, Kim MS, Yoo NJ, Lee SH, et al
    Mutational analysis of hypermutation-related POLE gene in acute leukemias and lymphomas.
    Exp Hematol. 2017;48:39-40.
    PubMed     Text format    


    March 2017
  70. GHOSH J, Kapur R
    Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia.
    Exp Hematol. 2017 Mar 22. pii: S0301-472X(17)30063.
    PubMed     Text format     Abstract available


  71. CLARKE CJ, Holyoake TL
    Preclinical approaches in chronic myeloid leukemia: from cells to systems.
    Exp Hematol. 2017;47:13-23.
    PubMed     Text format     Abstract available


  72. UTTARKAR S, Frampton J, Klempnauer KH
    Targeting the transcription factor Myb by small-molecule inhibitors.
    Exp Hematol. 2017;47:31-35.
    PubMed     Text format     Abstract available


  73. BOGEN A, Buske C, Hiddemann W, Bohlander SK, et al
    Variable aldehyde dehydrogenase activity and effects on chemosensitivity of primitive human leukemic cells.
    Exp Hematol. 2017;47:54-63.
    PubMed     Text format     Abstract available


    February 2017
  74. YOKOYAMA A
    Transcriptional activation by MLL fusion proteins in leukemogenesis.
    Exp Hematol. 2017;46:21-30.
    PubMed     Text format     Abstract available


    January 2017
  75. AN X, Liu J, Wang N, Wang D, et al
    AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes.
    Exp Hematol. 2017;45:36-44.
    PubMed     Text format     Abstract available


    May 2016
  76. TESTA U, Labbaye C, Castelli G, Pelosi E, et al
    Oxidative Stress and Hypoxia in Normal and Leukemic Stem Cells.
    Exp Hematol. 2016 May 11. pii: S0301-472X(16)30116.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: